search
Back to results

Effect of Probiotic on Rhinovirus Induced Colds (MK EPRIC)

Primary Purpose

Common Cold

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Bifidobacterium animalis subsp. lactis Bl-04
sucrose
Sponsored by
University of Virginia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Common Cold

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

INCLUSION CRITERIA AT ENROLLMENT:

  • Subject must be 18-60 years of age.
  • Subject must read and sign a copy of the approved Consent Form
  • Subject must have a serum neutralizing antibody titer of less than or equal to 1:4 to rhinovirus type 39

INCLUSION CRITERIA AT DAY -28

• Female subjects must be using an effective birth control method.

INCLUSION CRITERIA AT CHALLENGE:

  • Female subjects must be using an effective birth control method.

Exclusion Criteria:

  • Antibiotic use within 3 months prior to day -28

    • Female subjects with a positive urine pregnancy screen
    • History of use of probiotics in the preceding two weeks
    • Current cancer diagnosis or immunosuppressive therapy in the last 6 months
    • Any clinically significant abnormalities of the upper respiratory tract
    • Any clinically significant acute or chronic respiratory illness
    • Any clinically significant bleeding tendency by history
    • Hypertension that requires treatment with antihypertensive medications
    • History of angina or other clinically significant cardiac disease
    • Any medical condition that in the opinion of the Principal Investigator is cause for exclusion from the study
    • History of regular use (more than 3 days in 7) of tobacco products within the preceding two weeks
    • History of drug or alcohol abuse in the 6 months preceding the study

EXCLUSION CRITERIA AT CHALLENGE:

  • Any upper respiratory infection or allergic rhinitis in the two weeks prior to the challenge
  • Female subjects with positive pregnancy screen prior to challenge
  • Any medical condition that in the opinion of the Principal Investigator is cause for exclusion from the study
  • Use of any anti-inflammatory (steroids or NSAIDs) or cough/cold or allergy preparation in the two weeks prior to the challenge

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Placebo Comparator

    Arm Label

    Bifidobacterium lactis Bl-04

    Placebo

    Arm Description

    2*109 cfus of probiotic Bifidobacterium lactis Bl-04 (DuPont Nutrition and Health) mixed with 1g of sucrose as a carrier

    sucrose

    Outcomes

    Primary Outcome Measures

    Number of Participants With Rhinovirus-associated Illness Episodes
    Rhinovirus-associated illness episodes: Volunteers who have both a rhinovirus infection and a symptomatic illness will be defined as having a rhinovirus-associated common cold illness.

    Secondary Outcome Measures

    Full Information

    First Posted
    February 8, 2016
    Last Updated
    March 16, 2020
    Sponsor
    University of Virginia
    Collaborators
    Danisco Sweeteners Oy
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02679807
    Brief Title
    Effect of Probiotic on Rhinovirus Induced Colds
    Acronym
    MK EPRIC
    Official Title
    Effect of Probiotic on Rhinovirus Induced Colds
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2020
    Overall Recruitment Status
    Completed
    Study Start Date
    February 2016 (undefined)
    Primary Completion Date
    April 2018 (Actual)
    Study Completion Date
    April 2018 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    University of Virginia
    Collaborators
    Danisco Sweeteners Oy

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This is a randomized, double-blind placebo controlled trial to evaluate the effect of a probiotic (Bl-04) on the occurrence of rhinovirus-associated common cold illness in the experimental rhinovirus challenge model. A previous study documented that Bl-04 has significant effects on the innate immune response in the nose and this study will be powered to assess whether these effects translate into a demonstrable clinical benefit. Volunteers will be given Bl-04 or placebo for 28 days then challenged with rhinovirus. The primary analysis will be on the proportion of volunteers who develop a rhinovirus associated illness in the two treatment groups.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Common Cold

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    380 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Bifidobacterium lactis Bl-04
    Arm Type
    Active Comparator
    Arm Description
    2*109 cfus of probiotic Bifidobacterium lactis Bl-04 (DuPont Nutrition and Health) mixed with 1g of sucrose as a carrier
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    sucrose
    Intervention Type
    Biological
    Intervention Name(s)
    Bifidobacterium animalis subsp. lactis Bl-04
    Intervention Type
    Other
    Intervention Name(s)
    sucrose
    Primary Outcome Measure Information:
    Title
    Number of Participants With Rhinovirus-associated Illness Episodes
    Description
    Rhinovirus-associated illness episodes: Volunteers who have both a rhinovirus infection and a symptomatic illness will be defined as having a rhinovirus-associated common cold illness.
    Time Frame
    5 days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    60 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: INCLUSION CRITERIA AT ENROLLMENT: Subject must be 18-60 years of age. Subject must read and sign a copy of the approved Consent Form Subject must have a serum neutralizing antibody titer of less than or equal to 1:4 to rhinovirus type 39 INCLUSION CRITERIA AT DAY -28 • Female subjects must be using an effective birth control method. INCLUSION CRITERIA AT CHALLENGE: Female subjects must be using an effective birth control method. Exclusion Criteria: Antibiotic use within 3 months prior to day -28 Female subjects with a positive urine pregnancy screen History of use of probiotics in the preceding two weeks Current cancer diagnosis or immunosuppressive therapy in the last 6 months Any clinically significant abnormalities of the upper respiratory tract Any clinically significant acute or chronic respiratory illness Any clinically significant bleeding tendency by history Hypertension that requires treatment with antihypertensive medications History of angina or other clinically significant cardiac disease Any medical condition that in the opinion of the Principal Investigator is cause for exclusion from the study History of regular use (more than 3 days in 7) of tobacco products within the preceding two weeks History of drug or alcohol abuse in the 6 months preceding the study EXCLUSION CRITERIA AT CHALLENGE: Any upper respiratory infection or allergic rhinitis in the two weeks prior to the challenge Female subjects with positive pregnancy screen prior to challenge Any medical condition that in the opinion of the Principal Investigator is cause for exclusion from the study Use of any anti-inflammatory (steroids or NSAIDs) or cough/cold or allergy preparation in the two weeks prior to the challenge

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    34927036
    Citation
    Turner RB, Lehtoranta L, Hibberd A, Mannikko S, Zabel B, Yeung N, Huttunen T, Burns FR, Lehtinen MJ. Effect of Bifidobacterium animalis spp. lactis Bl-04 on Rhinovirus-Induced Colds: A Randomized, Placebo-Controlled, Single-Center, Phase II Trial in Healthy Volunteers. EClinicalMedicine. 2021 Dec 3;43:101224. doi: 10.1016/j.eclinm.2021.101224. eCollection 2022 Jan.
    Results Reference
    derived

    Learn more about this trial

    Effect of Probiotic on Rhinovirus Induced Colds

    We'll reach out to this number within 24 hrs